B. Taite

发表

Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist

R. Anders, A. Salyers, J. A. Szalony, 2001, Medicinal research reviews.

SC-49992--a potent and specific inhibitor of platelet aggregation.

T. Giorgio, L. Feigen, V. Engleman, 1994, Thrombosis research.

In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent.

R. Gorczynski, M. E. Zupec, A. Salyers, 1991, Thrombosis research.

Pharmacological Intervention at Disparate Sites in the Coagulation Cascade: Comparison of Anti-thrombotic Efficacy vs. Bleeding Propensity in a Rat Model of Acute Arterial Thrombosis

T. Girard, J. A. Szalony, N. Nicholson, 2002, Journal of Thrombosis and Thrombolysis.

Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist

R. Anders, A. Salyers, J. A. Szalony, 2001, Medicinal research reviews.

Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirin.

L. Feigen, A. Salyers, J. A. Szalony, 1998, Circulation.

Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A.

D. Mehrotra, L. Feigen, A. Salyers, 1995, Circulation.

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor.

J. Zablocki, M. Miyano, N. Nicholson, 1993, Journal of medicinal chemistry.

Assessment of platelet function assays.

L. Feigen, L P Feigen, D M Lansky, 1998, American heart journal.

SC-54684A: an orally active inhibitor of platelet aggregation.

J. Zablocki, B. Keller, A. Salyers, 1995, Circulation.

Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation.

D. Mehrotra, L. Feigen, N. Nicholson, 1993, Journal of pharmacological and toxicological methods.

Evaluation of a stable 5-F prostacyclin analogue as an antithrombotic agent in haemodialysis.

N. Nicholson, G. Fuller, B. Taite, 1986, Drugs under experimental and clinical research.

3-Alkyl-3-hydroxyglutaric acids: a new class of hypocholesterolemic HMG CoA reductase inhibitors. 1.

D. D. Langford, J. Miller, E. Rohrbacher, 1985, Journal of medicinal chemistry.

Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749).

R. Gorczynski, M. E. Zupec, A. Salyers, 1991, Journal of Pharmacology and Experimental Therapeutics.